Immune Regulation News Volume 15.40 | Oct 20 2023

    By
    Laurisa Dohm
    -
    0
    9








    2023-10-20 | IRN 15.40


    Immune Regulation News by STEMCELL Technologies
    Vol. 15.40 – 20 October, 2023
    TOP STORY

    Dietary Fructose-Mediated Adipocyte Metabolism Drives Antitumor CD8+ T Cell Responses

    Transcriptional profiling of tumor-infiltrating CD8+ T cells revealed that dietary fructose mediated attenuated transition of CD8+ T cells to terminal exhaustion, leading to a superior antitumor efficacy.
    [Cell Metabolism]

    AbstractGraphical Abstract
    PUBLICATIONSRanked by the impact factor of the journal

    Integrin α3 Promotes TH17 Cell Polarization and Extravasation during Autoimmune Neuroinflammation

    Mechanistically, integrin α3 enhanced the immunological synapse formation to promote the polarization and proliferation of TH17 cells.
    [Science Immunology]

    Abstract

    IL-31–Dependent Neurogenic Inflammation Restrains Cutaneous Type 2 Immune Response in Allergic Dermatitis

    Investigators examined the consequences of disrupting Il31 and its receptor Il31ra in a mouse model of house dust mite–induced allergic dermatitis.
    [Science Immunology]

    Full ArticlePress Release

    Zfp335 Establishes eTreg Lineage and Neonatal Immune Tolerance by Targeting Hadha-Mediated Fatty Acid Oxidation

    Scientists showed that Zfp335 deletion in Tregs failed to differentiate into effector Tregs (eTregs) and lost Treg-suppressive function, and that KO mice exhibited early-onset lethal autoimmune inflammation with unrestricted activation of conventional T cells.
    [Journal Of Clinical Investigation]

    Full ArticleGraphical Abstract

    Global Lactylome Reveals Lactylation-Dependent Mechanisms Underlying TH17 Differentiation in Experimental Autoimmune Uveitis

    Lactylation levels in CD4+ T cells increased with the progression of experimental autoimmune uveitis (EAU), andiInhibition of lactylation suppressed TH17 differentiation and attenuated EAU inflammation.
    [Science Advances]

    Full Article

    Rapamycin Nanoparticles Increase the Therapeutic Window of Engineered Interleukin-2 and Drive Expansion of Antigen-Specific Regulatory T Cells for Protection against Autoimmune Disease

    Researchers demonstrated that the combination of biodegradable nanoparticles encapsulating rapamycin and an engineered Treg-selective IL-2 variant increased the number and durability of total Tregs, as well as induced a profound synergistic increase in antigen-specific Tregs when combined with a target antigen.
    [Journal Of Autoimmunity]

    Full Article

    T Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids

    To address immune rejection, the authors investigated the impact of genetically modifying human leukocyte antigen class I in kidney organoids prior to transplantation.
    [Stem Cells Translational Medicine]

    Full ArticleGraphical Abstract

    Autotaxin in Encephalitogenic CD4 T Cells as a Therapeutic Target for Multiple Sclerosis

    Myelin activated CD4 T cells upregulated expression of autotaxin in vitro, and ex vivo analysis of central nervous system-infiltrating CD4 T cells showed significantly higher autotaxin expression compared to cells from healthy mice.
    [European Journal Of Immunology]

    Abstract
    See how small molecules affect key signaling pathways in cancer research. Download your free wallchart now.
    REVIEWS

    The Cancer-Immune Dialogue in the Context of Stress

    Scientists explore the complex circuitries that link stress to perturbations in the cancer-immune dialogue and their implications for therapeutic approaches to cancer.
    [Nature Reviews Immunology]

    Full Article

    Celiac Disease: Mechanisms and Emerging Therapeutics

    The authors summarize our current understanding of Celiac disease pathogenesis and how it is being harnessed for therapeutic design and development.
    [Trends In Pharmacological Sciences]

    Abstract
    INDUSTRY AND POLICY NEWS

    FDA Clears Rise Therapeutics’ IND Application to Initiate a Phase I Clinical Study of Its Novel Oral Immunotherapy for the Treatment of Rheumatoid Arthritis

    Designed specifically to induce regulatory T cells and reset immune balance in patients suffering from autoimmunity, R-2487 works by educating dendritic cells to redirect immune responses away from inflammatory effects.
    [Rise Therapeutics]

    Press Release
    FEATURED EVENT

    Cell Therapy for Autoimmune Disease Summit

    November 28 – 30, 2023
    Philadelphia, Pennsylvania, United States

    > See All Events

    JOB OPPORTUNITIES

    Assistant Professor – Immunology

    Harvard Medical School – Boston, Massachusetts, United States

    Postdoctoral Associate – Immune Cells in Blood Diseases and GvHD

    Baylor College of Medicine – Houston, Texas, United States

    Doctoral Positions – Biomedical Research

    Berlin Institute of Health at Charit̩ РBerlin, Germany

    Postdoctoral Researcher – Cancer Immunotherapy Research

    University of Turku – Turku, Finland

    Assistant Professor – Immunology

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Immune Regulation News Twitter